[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482434":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":19,"locations":7,"responsibleParty":25,"collaborators":7,"id":27,"slug":7,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":7,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":32,"phases":7,"briefSummary":33,"conditions":34,"keywords":36,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Incyte Corporation","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"DRUG","Itacitinib",[13],"INCB039110",[15],{"name":16,"affiliation":17,"role":18},"Lisa Forbes Satter, MD","Baylor College of Medicine","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Incyte Corporation Call Center (US)","CONTACT","1.855.463.3463","medinfo@incyte.com",{"type":26,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100482434",false,"NCT05561985","Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Expanded access use of Itacitinib to treat a single patient with aplastic anemia.",[35],"STAT1 Gain-of-Function Disease",[37],"STAT1 GOF disease","AVAILABLE","2026-06-09",{"date":41,"type":42},"2026-06-10","ACTUAL",{"name":5,"class":6}]